GlassScriptPhysician profile
Linh Tran
NPI 1235884941
$2,104.08
in general payments reported to CMS, 2019-2025
18 companies · $1,495 in 2025
The $1,495 reported for 2025 was more than what 88% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $609 · 2025: $1,495.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,104.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $300.76 | 2024-2025 | Lybalvi, Aristada |
| E.R. Squibb & Sons, L.L.C. | $255.56 | 2024-2025 | Cobenfy |
| Neurocrine Biosciences, INC. | $251.72 | 2025 | |
| Abbvie INC. | $224.26 | 2024-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $165.95 | 2024-2025 | Caplyta |
| Almatica Pharma LLC | $127.96 | 2024-2025 | Loreev Xr |
| Acadia Pharmaceuticals INC | $124.78 | 2024 | Nuplazid |
| Vanda Pharmaceuticals INC. | $107.63 | 2024-2025 | Fanapt, Hetlioz |
| Janssen Pharmaceuticals, INC | $92.41 | 2024-2025 | Invega Sustenna, Invega Trinza |
| Otsuka America Pharmaceutical, INC. | $91.23 | 2024-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Collegium Pharmaceutical, INC. | $73.38 | 2025 | Jornay Pm |
| Lundbeck LLC | $71.72 | 2024-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $69.97 | 2024-2025 | Uzedy |
| Neos Therapeutics, LP | $43.27 | 2025 | Cotempla Xr-Odt, Adzenys Xr-Odt |
| Noven Therapeutics, LLC | $39.37 | 2024-2025 | Xelstrym |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $23.44 | 2025 | Quviviq |
| Axsome Therapeutics, INC. | $20.63 | 2025 | Auvelity |
| Vertical Pharmaceuticals, LLC | $20.04 | 2025 | Relexxii |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Linh Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.